MARKET

GRAL

GRAL

Grail Inc
NASDAQ
35.78
+3.29
+10.11%
After Hours: 35.54 -0.24 -0.66% 19:43 05/02 EDT
OPEN
33.06
PREV CLOSE
32.49
HIGH
36.36
LOW
33.06
VOLUME
1.69M
TURNOVER
--
52 WEEK HIGH
63.99
52 WEEK LOW
12.33
MARKET CAP
1.26B
P/E (TTM)
-0.5630
1D
5D
1M
3M
1Y
5Y
1D
Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling
Seeking Alpha · 1d ago
A great week for institutional investors who own 57% of GRAIL, Inc. (NASDAQ:GRAL)
Simply Wall St · 4d ago
Weekly Report: what happened at GRAL last week (0421-0425)?
Weekly Report · 5d ago
GRAIL To Present New Data On Galleri MCED Test And Additional Data From GRAIL's ctDNA-based Targeted Methylation Platform At AACR Annual Meeting In Chicago
Benzinga · 04/22 20:04
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Benzinga · 04/22 16:09
This Cancer Test Could Become Routine -- and a Big Seller, Says Analyst
Barron‘s · 04/21 20:47
Weekly Report: what happened at GRAL last week (0414-0418)?
Weekly Report · 04/21 12:47
GRAIL Price Target Announced at $32.00/Share by Canaccord Genuity
Dow Jones · 04/21 11:07
More
About GRAL
More
GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
Recently
Symbol
Price
%Change

Webull offers Grail Inc stock information, including NASDAQ: GRAL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRAL stock methods without spending real money on the virtual paper trading platform.